Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

The technology described herein relates to siRNAs, e.g., methods and compositions relating to the production of siRNAs in bacterial cells.

The invention provides compositions and methods of making and using effector oligonucleotides, including effector oligonucleotides with greater than one mismatch as compared to its target sequence. These effector oligonucleotides are useful for improving the efficiency of genomic editing as well as providing therapeutic benefits to individuals in need thereof.

Recombinant cells and methods for producing methyl ketones, such as medium-chain methyl ketones. The recombinant cells include recombinant acyl-ACP thioesterase genes, recombinant β-ketoacyl-CoA thioesterase genes, and recombinant acyl-CoA synthetase genes, in addition to other modifications. The methods include culturing the recombinant cells to produce the methyl ketones and isolating the produced methyl ketones.

The present invention relates to a method for improving the production of a difficult-to-express recombinant protein in a recombinant microorganism, and more particularly to a method for improving the production of a difficult-to-express recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced. According to the present invention, expressions of a large recombinant protein, a difficult-to-express protein and a useful protein can be dramatically increased by reducing expression of the rnpA gene.

This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like RNA (shRNA) compositions, such as microRNA precursors (pre-miRNA) and short interfering RNAs (siRNA), which are useful for treating human ageing related diseases, such as, but not limited, Alzheimer's diseases, Parkinson's diseases, osteoporosis, diabetes, and cancers. The novelty of the present invention is to create an artificially enhanced adaptation environment for prokaryotic cells to adopt eukaryotic pol-2 and/or pol-2-like promoters for transcribing desired ncRNAs and/or their precursors without going through error-prone prokaryotic promoters, so as to improve the productive efficiency and reading fidelity of the shRNA transcription in the prokaryotic cells. The resulting shRNAs, preferably pre-miRNAs and siRNAs, are useful for developing therapeutic drugs against human degenerative diseases, particularly through a mechanism to induce CD34-positive stem cell expansion and/or regeneration.

The present invention relates to methods of treating, preventing, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of an inflammatory skin disease, condition or lesion in a human subject, which include the step of administering to the subject a therapeutically effective amount of mi RNA compositions. In addition, methods of this invention may be used to treat symptoms of inflammatory skin diseases and reduce and/or inhibit keratinocyte proliferation.

The present disclosure provides, in some aspects, nucleic acid-based molecular tools that enable the recording of molecular structure and soluble signals as well as the programmed assembly of molecular structures.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.